被担保人眉山汇龙药业科技有限公司基本情况: 1、公司名称:眉山汇龙药业科技有限 2、成立日期:2015年11 3、注册资本:6,000万 4、住所:四川省眉山市东坡区窟山经济开发区新区本草大道北段 15 号 5、法定代表人:曾德志 注:上述 2024年 1-12 月财务数据已经天健会计师事务所(特殊普通合伙) 审计,2025年1-3月财务数据未经审计。 9、影响被担保人偿债能力的重大或有事项 截至目前,眉山汇龙不是失信被执行人,不存在影响被担保人偿债能力的重 大或有事项。与公司不存在产权、业务、资产、债权债务、人员等方面的其他关 系。 6、经营范围:许可项目:药品生产;药品批发(依法须经批准的项目,经 相关部门批准后方可开展经营活动,具体经营项目以相关部门批准文件或许可证 件为准)一般项目:医学研究和试验发展;技术服务、技术开发、技术咨询、技 术交流、技术转让、技术推广;技术进出口;货物进出口(除依法须经批准的项 目外,凭营业执照依法自主开展经营活动）。 7、股权结构:公司持股比例为100% 8、最近一年又一期的主要财务指标 眉山汇龙作为公司首次公开发行募集资金投资项目"年产 395 千克多肽原料 药生产线项 ...

被担保人成都圣诺生物 司基本情况: 6、经营范围:许可项目:药品生产;药品批发;危险化学品生产;道路货 物运输(不含危险货物)。(依法须经批准的项目,经相关部门批准后方可开展 经营活动,具体经营项目以相关部门批准文件或许可证件为准）一般项目:医学 研究和试验发展;技术服务、技术开发、技术咨询、技术交流、技术转让、技术 推广;技术进出口;货物进出口。(除依法须经批准的项目外,凭营业执照依法 自主开展经营活动) 7、股权结构:公司持股比例为 100% 8、最近一年又一期的主要财务指标 单位:人民币、万元 | 项目 | 2025年3月31日 | 2024 年 12月 31 日 | | --- | --- | --- | | | (未经审计) | (经审计) | | 资产总额 | 99,836.35 | 95,806.12 | | 负债总额 | 51,662.00 | 52.693.86 | | 净资产 | 48.174.35 | 43,112.26 | | 项目 | 2025年1-3月 | 2024 年 1-12 月 | | | (未经审计) | (经审计) | | 营业收入 | 17,481.39 | 42.97 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-013 成都圣诺生物科技股份有限公司 关于变更公司经营范围、注册地址、修订《公司章程》 及部分治理制度并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 成都圣诺生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第二十五次会议，审议通过了《关于变更公司经营范围、 修订<公司章程>及部分治理制度并办理工商变更登记的议案》，该议案尚需提 交公司股东大会审议。现将相关情况公告如下： 根据《上市公司章程指引（2025 年修订）》《上海证券交易所科创板股票 上市规则（2024 年 4 月修订）》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作（2023 年 12 月修订）》等规范性文件的规定，结合公 司实际情况，公司拟对《成都圣诺生物科技股份有限公司章程》（以下简称 "《公司章程》"）以及《股东会议事规则》《独立董事工作制度》等内部管 理制度进行修改，具体情况如下： 一、公司经营范围、注册 ...

圣诺生物公告，2024年营业收入为4.56亿元，同比增长4.84%。归属于上市公司股东的净利润5002.37万 元，同比下降28.88%。公司拟向全体股东每10股分派现金红利1.4元(含税)，合计拟派发现金红利 1573.86万元(含税)，占公司2024年度归属于母公司股东净利润的比例为31.46%。同时以资本公积金转增 股本方式向全体股东每10股转增4股，合计转增4496.74万股，转增后公司总股本变更为1.57亿股。 ...

数据显示，2021年至2023年，公司实现营业收入分别为3.87亿元、3.96亿元、4.35亿元，同比增长 2.05%、2.38%、9.93%；归母净利润分别为6125万元、6449万元、7034万元，同比增长2.09%、5.28%、 9.08%。2024年，公司实现营业总收入4.55亿元，较上年同期增长4.67%；尽管归属于母公司股东的净利 润为5473.63万元，同比下降22.18%，但这主要受到研发投入增加、集采降价传导和海外扩张成本上升 等因素的影响，公司依然在多肽药物领域保持了较强的市场竞争力。 2025年一季度，公司多肽原料药业务继续发力，销售收入实现同比大幅增长，成为公司业绩增长的主要 驱动力。3月30日，公司公告称，预计2025年一季度归属于上市公司股东的净利润为3919.85万至4790.92 万元，同比增长137.97%至190.85%；扣除非经常性损益后的净利润为3983.96万至4869.29万元，同比增 长160.62%至218.54%。 完善海外市场布局 圣诺生物近年来持续加大产能扩建力度，多个募投项目正稳步推进。 多肽类创新药公司圣诺生物（688117.SH）业绩迎来大幅增长。 ...

圣诺生物688117 时间: 2025年3月31日星期一 62.19分综合得分 较强 趋势方向 主力成本分析 29.30 元 当日主力成本 25.27 元 5日主力成本 23.77 元 0 次 20日主力成本 24.23 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 1次 跌停 技术面分析 24.65 短期压力位 23.20 短期支撑位 24.65 中期压力位 22.46 中期支撑位 股价突破短期压力位，短线有望走强； 股价突破中期压力位，中线有望走强 K线形态 ★跳空缺口★ 关联行业/概念板块 注意向上还是向下跳空，出现向上跳空缺口，并伴有较大的成交量时，可积极参与；若出现向下 跳空缺口，说明市况已发生逆转，原来的升势已经结束，继续下跌的可能性很大 ★光头阳线★ 后市看涨 ★大阳烛★ 看涨 ★多方炮★ 在底部出现有上涨可能，在中间出现有可能是上涨中继，顶部出现是复合见顶信号 资金流数据 2025年03月31日的资金流向数据方面 | 主力资金净流入4892.05万元 | | --- | | 占总成交额11% | | 超大单净流入6595.13万元 | | 大单净流出1703.08万元 | | 散户资 ...

Core Viewpoint - Shengnuo Biotech (688117) experienced a significant stock price increase due to its strong Q1 2025 earnings forecast, with a projected net profit increase of 137.97% to 190.85% year-on-year [1] Company Summary - Shengnuo Biotech specializes in the research and development of peptide-based innovative drugs, providing pharmaceutical research and custom production services, as well as developing and selling peptide generic drugs and production technology transfer services [1] - The company reported a projected net profit for Q1 2025 between 39.19 million to 47.91 million yuan, marking a year-on-year increase of 22.73 million to 31.44 million yuan [1] - Shengnuo Biotech's peptide raw material business saw significant sales growth in Q1 2025, contributing to the overall performance increase [1] Industry Summary - Peptide drugs, known for their higher activity and selectivity compared to small molecule drugs, have been gaining traction in treating complex diseases [2] - The global peptide drug market has been steadily growing, with China's peptide drug market also on the rise [2] - Shengnuo Biotech has developed 19 self-researched peptide raw material varieties, with several products receiving production approvals in both domestic and international markets [2] - Competitors like Nuotai Biotech and WuXi AppTec are also reporting strong growth in their peptide-related businesses, indicating a competitive and expanding market [3]

Group 1 - The company expects a net profit attributable to shareholders of the parent company for Q1 2025 to be between 39.1985 million yuan and 55.000 million yuan, representing an increase of 137.97% to 190.85% compared to the same period last year [1][2] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 39.8396 million yuan and 48.6929 million yuan, which is an increase of 160.62% to 218.54% year-on-year [1][2] - The company reported a net profit of 16.4722 million yuan for the same period last year, with a net profit of 15.2864 million yuan after deducting non-recurring gains and losses [1][2] Group 2 - The significant increase in performance is attributed to the company's alignment with the development trends in the peptide industry and the expansion of its domestic and international marketing efforts, leading to substantial growth in sales revenue from peptide raw materials in Q1 2025 [2]

Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for Q1 2025 to be between 39.1985 million and 47.9092 million yuan, representing a year-on-year increase of 137.97% to 190.85%[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 39.8396 million and 48.6929 million yuan, an increase of 160.62% to 218.54% year-on-year[3]. - The net profit for the same period last year was 16.4722 million yuan, with a net profit of 15.2864 million yuan after deducting non-recurring gains and losses[5]. Business Growth Factors - The significant increase in performance is attributed to the company's expansion in the peptide raw material drug business, which saw substantial sales growth in Q1 2025[6]. Earnings Forecast Reliability - The company has not identified any major uncertainties that could affect the accuracy of this earnings forecast[8]. - The earnings forecast is based on preliminary calculations by the company's financial department and has not yet been audited by certified public accountants[4]. - Investors are advised that the above forecast data is preliminary and the accurate financial data will be disclosed in the official Q1 2025 report[9].

Group 1 - The stock of Shengnuo Bio (688117) has a comprehensive score of 53.14, indicating a strong performance [1] - The main cost analysis shows that the current main cost is 24.65 CNY, with a 5-day average of 23.86 CNY and a 20-day average of 24.20 CNY [1] - The stock has not experienced any limit-up or limit-down events in the past year [1] Group 2 - The short-term resistance level is at 24.29 CNY, while the short-term support level is at 23.20 CNY [2] - The stock price has broken through the short-term resistance level, suggesting a potential short-term strength, although the mid-term trend remains unclear [2] - The K-line patterns indicate a long lower shadow and a "red three soldiers" formation, suggesting a possible bottoming and recovery [2] Group 3 - On March 27, 2025, the net inflow of main funds was 836.38 million CNY, accounting for 10% of the total transaction volume [2] - Large orders contributed a net inflow of 618.84 million CNY, while retail investors experienced a net outflow of 137.51 million CNY [2] - Related industry sectors include chemical pharmaceuticals (1.82%), assisted reproduction (0.45%), infant and child concepts (0.30%), and weight loss drugs (2.07%) [2]